logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Kangchen Pharmaceutical (01681.HK) spent 1.1079 million Hong Kong dollars to repurchase 100,000 shares on June 20th.

date
20/06/2025
The China Fortune Finance APP reported that Sinopharm Group Co., Ltd. (01681.HK) announced that it will spend HK$1.1079 million to repurchase 100,000 shares on June 20, 2025.
Latest
3 m ago
NCR Atleos (NATL.US) received initial coverage from Wedbush, with an outperform rating and a price target of $35.00.
4 m ago
Peng Shun International (06163): Independent Non-Executive Director Guo Wanlin appointed as a member of the nomination committee.
4 m ago
Jemiet: Planning to purchase the controlling stake of Stonyheart through a cash transaction may constitute a significant asset restructuring.
5 m ago
Wedbush: Reaffirming rating for Tesla (TSLA.US) from outperform to outperform, with a target price adjustment from $500.00 to $500.00.
5 m ago
The unemployment rate in Slovakia in May is 4.82%.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.